Share Prices & Company Research

Stockbroking

Astrazeneca Plc

Current Price 10419.00p Bid 10410.00p Ask 10462.00p Change 1.41%
Last Updated: 24/12/2024 03:46. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Financial Highlights Year Ended 31/12/2023

Revenue
£45,811.00m
Operating Profit/Loss
£8,193.00m
Dividend yield (%)
2.20
Total dividend for year
$n/a
Dividend cover
1.32
P/E Ratio
34.50
More Financials

Key Personnel

Mr Pascal Soriot
CEO and Executive director
Dr Aradhana Sarin
CFO & Executive Director
Dr Euan Ashley
Non-Executive Director
Mr Andreas Rummelt
Non-Executive Director
Mr Marcus Wallenberg
Non-Executive Director
Mr Michel Demare
Non-Executive Director
Mr Philip A J Broadley
Non-Executive Director
Mr Tony Mok
Non-Executive Director
Mrs Deborah DiSanzo
Non-Executive Director
Mrs Nazneen Rahman
Non-Executive Director
Mrs Sheri McCoy
Non-Executive Director
Ms Anna Manz
Non-Executive Director
Ms Diana Layfield
Non-Executive Director

Stock Details

EPIC
AZNL
ISIN
GB0009895292
Shares in Issue
1,264.16m
Market cap
£131,713.12m

Analyst Views (4)

Strong Buy
 
0%
Buy
 
75.00%
Hold
 
25.00%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
10,419.00p
Bid Price
10,410.00p
Ask Price
10,462.00p
Volume
338,135
Change Today
145.00p
% Change Today
1.41%
Open
10,332.00p
Previous Close
10,419.00p
Intraday High
10,464.00p
Intraday Low
10,306.00p
52 Week High
13,250.00p
52 Week Low
9,521.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

AstraZeneca lung cancer drug Tagrisso approved by EU regulators 23/12/2024 07:17:11 AstraZeneca cancer drug secures US approval 05/12/2024 08:48:40 AstraZeneca appoints Iskra Reic as vice-president of intl unit 04/12/2024 14:00:17 AstraZeneca reports positive results from prostate cancer trial 25/11/2024 07:17:56 AstraZeneca's Tagrisso recommended for EU approval 18/11/2024 09:11:10 Sunday newspaper round-up: Kursk, AstraZeneca, BAE Systems 17/11/2024 18:14:19 Director dealings: AstraZeneca CEO ups stake 15/11/2024 16:11:27 London close: Stocks end turbulent week in the red 15/11/2024 15:21:20 London close: Stocks sink as UK jobless rate rises 12/11/2024 16:39:10 AstraZeneca upgrades full-year guidance amid strong momentum 12/11/2024 07:17:09 AstraZeneca "excited" by positive results in Tezspire clinical trial 08/11/2024 07:19:04 AstraZeneca says does not comment on media reports as shares slump 05/11/2024 17:18:46 AstraZeneca China president under investigation 30/10/2024 13:37:47 AstraZeneca's nerve damage treatment recommended for approval in EU 21/10/2024 07:10:33 Hutchmed reports positive results from AstraZeneca lung cancer collaboration 16/10/2024 11:41:08 AstraZeneca enters into exclusive license agreement with CSPC 07/10/2024 10:16:42 AstraZeneca's Tagrisso gets new US lung cancer approval 26/09/2024 07:38:03 AstraZeneca breast cancer drug trial fails to improve overall survival 23/09/2024 07:17:35 AstraZeneca's inflammatory disease drug Fasenra approved in the US 18/09/2024 07:29:03 London close: Stocks finish firmer in subdued trading 13/09/2024 16:44:31 London close: Stocks mixed on latest UK jobs data 10/09/2024 14:47:09 AstraZeneca shares drop on lung cancer trial update 10/09/2024 09:54:33 AstraZeneca's Imfinzi gets fresh approval in the US 16/08/2024 07:15:33 AstraZeneca prices EUR 1.4bn eurobond offering 30/07/2024 11:56:49 London close: Stocks finish mixed at start of busy week 29/07/2024 15:35:26

Income Statement

Year End Date
31 Dec 2023
31 Dec 2022
 
$ (M)
$ (M)
Continuing Operations
Revenue
45,811.00
44,351.00
Operating Profit/Loss
8,193.00
3,757.00
Net Interest
-1,282.00
-1,251.00
Pre-Tax Profit
6,899.00
2,501.00
Profit After Tax from continuing operations
5,961.00
3,293.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
5,961.00
3,293.00
Attributable to:
Equity Holders of Parent Company
5,955.00
3,288.00
Minority Interests
6.00
5.00
Total Dividend Paid
$n/a
$n/a
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2023
31 Dec 2022
Basic
384.00c
212.00c
Diluted
381.00c
211.00c
Adjusted
384.00c
212.00c
Dividend per Share
$n/a
$n/a

Assets

Year End Date
31 Dec 2023
31 Dec 2022
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
10,502.00
9,449.00
Intangible Assets
58,137.00
59,127.00
Investment Properties
n/a
n/a
Investments
1,677.00
1,142.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
5,749.00
4,172.00
Current Assets
Inventories
5,424.00
4,699.00
Trade & Other Receivables
13,552.00
11,252.00
Cash at Bank & In Hand
5,840.00
6,166.00
Current Asset Investments
122.00
239.00
Other Current Assets
116.00
87.00
Other Assets
n/a
150.00
Total Assets
101,119.00
96,483.00

Liabilities

Year End Date
31 Dec 2023
31 Dec 2022
 
$ (M)
$ (M)
Current Liabilities
Borrowings
5,400.00
5,542.00
Other Current Liabilities
25,142.00
20,751.00
Total Current Liabilities
30,542.00
26,293.00
Non-Current Liabilities
Borrowings
23,222.00
23,690.00
Provisions
3,971.00
3,840.00
Other Non-Current Liabilities
4,218.00
5,602.00
Total Non-Current Liabilities
31,411.00
33,132.00
Other Liabilities
n/a
n/a
Total Liabilities
61,953.00
59,425.00

Net Assets

Year End Date
31 Dec 2023
31 Dec 2022
 
$ (M)
$ (M)
Net Assets
39,166.00
37,058.00

Capital & Reserves

Year End Date
31 Dec 2023
31 Dec 2022
 
$ (M)
$ (M)
Share Capital
388.00
387.00
Share Premium Account
35,188.00
35,155.00
Other Reserves
2,065.00
2,069.00
Retained Earnings
1,502.00
-574.00
Shareholders Funds
39,143.00
37,037.00
Minority Interests/Other Equity
23.00
21.00
Total Equity
39,166.00
37,058.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
1st Interim
08 Aug 2024
09 Sep 2024
100.00¢
2nd Interim
22 Feb 2024
25 Mar 2024
197.00¢
1st Interim
10 Aug 2023
11 Sep 2023
93.00¢
2nd Interim
23 Feb 2023
27 Mar 2023
197.00¢
1st Interim
11 Aug 2022
12 Sep 2022
93.00¢
2nd Interim
24 Feb 2022
28 Mar 2022
197.00¢
1st Interim
12 Aug 2021
13 Sep 2021
90.00¢
2nd Interim
25 Feb 2021
29 Mar 2021
190.00¢
1st Interim
13 Aug 2020
14 Sep 2020
90.00¢
2nd Interim
27 Feb 2020
30 Mar 2020
190.00¢
1st Interim
08 Aug 2019
09 Sep 2019
90.00¢
2nd Interim
28 Feb 2019
27 Mar 2019
190.00¢
1st Interim
09 Aug 2018
10 Sep 2018
90.00¢
2nd Interim
15 Feb 2018
19 Mar 2018
190.00¢
1st Interim
10 Aug 2017
11 Sep 2017
90.00¢
2nd Interim
16 Feb 2017
20 Mar 2017
190.00¢
1st Interim
11 Aug 2016
12 Sep 2016
90.00¢
2nd Interim
17 Feb 2016
21 Mar 2016
190.00¢
1st Interim
13 Aug 2015
14 Sep 2015
90.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢

Dividend Metrics

Year End Date
31 Dec 2023
31 Dec 2022
Dividend growth
n/a%
1.05%
Dividend yield
2.20%
2.10%
Dividend cover
1.32
0.73


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.